---
title: 'Industry Daily Summary: What Happened on October 10, 2026'
headline: Prime Medicine doses first participant in Wilson disease trial
description: Cell and gene therapy executives discussed manufacturing scale, while
  Cellares estimated the loss of a contract could push commercial production back
  about a year.
url: https://thebench.bio/news/industry/2026-10-10
topic: industry
date: '2026-10-10'
covers:
- '2026-10-10'
date_published: '2026-10-11T00:01:45Z'
date_modified: '2026-10-11T00:01:45Z'
sources: 1
publisher: The Bench (thebench.bio)
---

# Industry Daily Summary: What Happened on October 10, 2026

**Prime Medicine doses first participant in Wilson disease trial**

Cell and gene therapy executives discussed manufacturing scale, while Cellares estimated the loss of a contract could push commercial production back about a year.

## Today in brief

Prime Medicine gave PM577a to the first participant in a Phase I/II trial for Wilson disease caused by the H1069Q mutation. [1] At a cell and gene therapy meeting, executives discussed commercial manufacturing, and Cellares estimated that losing its Bristol Myers Squibb agreement could delay production by about a year. [1]

## Prime starts its Wilson disease trial

The first participant has received PM577a in Prime Medicine's global Phase I/II study for Wilson disease with the H1069Q mutation. [1] Allen Reine expects clinical results in 2027 from the company's liver programs for Wilson disease and alpha-1 antitrypsin deficiency. [1]

## Cell and gene therapy companies weigh manufacturing scale

Executives at the 2026 Cell and Gene Meeting on the Mesa discussed ways to make cell and gene therapies at commercial scale. [1] Bristol Myers Squibb ended its manufacturing agreement with Cellares in August 2026, saying Cellares had not met commercial production requirements for Breyanzi. [1] Signed in April 2024, the agreement had a stated value of up to $380 million. [1] Cellares executive Fabian Gerlinghaus estimated the loss would set back commercial manufacturing by about a year. [1] Gerlinghaus said Cellares had more than doubled its customer base since the start of 2026 and aims to build a portfolio of 30 to 40 active programs using autologous cells modified outside the body. [1] Cellares was among eight companies selected for the FDA PreCheck program. [1]

## Also worth knowing

- Skylark Bio's Jodi Cook said reusing platform elements shortened development of its second indication to about 18 months, down from three and a half years for its first. [1]
- Japan's PMDA accepted Nanoscope Therapeutics' MOGENRY for priority review in inherited retinal dystrophies, supported by data in retinitis pigmentosa and Stargardt disease. [1]

## The day in numbers

- **1**: Participants dosed so far in Prime Medicine's Phase I/II Wilson disease study. [1]
- **2027**: Year Allen Reine expects clinical results from Prime's Wilson disease and alpha-1 antitrypsin deficiency liver programs. [1]
- **Up to $380 million**: Stated maximum value of Cellares' manufacturing agreement with Bristol Myers Squibb, which ended in August 2026. [1]
- **About a year**: Fabian Gerlinghaus's estimate of the commercial manufacturing delay after the agreement ended. [1]

## Sources

1. [Reporter’s Notebook: Cell and Gene Therapy’s Success Lies Beyond the Bespoke (Part 1)](<https://www.insideprecisionmedicine.com/topics/precision-medicine/reporters-notebook-cell-and-gene-therapys-success-lies-beyond-the-bespoke-part-1/>), Inside Precision Medicine, 2026-10-10

---

The Bench wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.insideprecisionmedicine.com/topics/precision-medicine/reporters-notebook-cell-and-gene-therapys-success-lies-beyond-the-bespoke-part-1/>